chf solutions is an early stage company focused on commercializing the aquadex flexflow system. our objective is to improve the quality of life for patients with heart failure and related conditions, such as fluid overload. at chf solutions, we are committed to the relentless pursuit of identifying and developing innovative solutions to address unmet clinical needs with the goal of benefiting patients, medical practitioners, and the broader healthcare community. if you are looking for a career where you can make difference we would like to hear from you. we are looking for highly skilled, highly motivated people who want to be part of a growing company where everything you do will matter. chf solutions is an equal opportunity/affirmative action employer committed to cultural diversity in the workplace.
Company profile
Ticker
NUWE
Exchange
Website
CEO
John L. Erb
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
CHF Solutions, Inc., Sunshine Heart, Inc.
SEC CIK
Corporate docs
Subsidiaries
Sunshine Heart Ireland Limited ...
IRS number
680533453
NUWE stock data
Latest filings (excl ownership)
S-1/A
IPO registration (amended)
17 Apr 24
PRE 14A
Preliminary proxy
9 Apr 24
8-K
Other Events
26 Mar 24
S-1/A
IPO registration (amended)
13 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
6 Mar 24
S-1/A
IPO registration (amended)
8 Feb 24
8-K
Other Events
6 Feb 24
S-1/A
IPO registration (amended)
5 Feb 24
S-1/A
IPO registration (amended)
30 Jan 24
Transcripts
NUWE
Earnings call transcript
2023 Q4
5 Mar 24
NUWE
Earnings call transcript
2023 Q3
7 Nov 23
NUWE
Earnings call transcript
2023 Q2
8 Aug 23
NUWE
Earnings call transcript
2023 Q1
9 May 23
NUWE
Earnings call transcript
2022 Q4
28 Feb 23
NUWE
Earnings call transcript
2022 Q3
8 Nov 22
NUWE
Earnings call transcript
2022 Q2
9 Aug 22
NUWE
Earnings call transcript
2022 Q1
10 May 22
NUWE
Earnings call transcript
2021 Q4
1 Mar 22
NUWE
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
Michael Kendrick McCormick
4 Jan 24
4
David McDonald
4 Jan 24
4
Archelle Georgiou Feldshon
4 Jan 24
3
David McDonald
1 Nov 23
3
Archelle Georgiou Feldshon
1 Nov 23
4
Robert Benjamin Scott
6 Sep 23
3
Robert Benjamin Scott
6 Sep 23
4
Michael Kendrick McCormick
5 Jun 23
3
Michael Kendrick McCormick
5 Jun 23
4
Jon W Salveson
23 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.93 mm | 4.93 mm | 4.93 mm | 4.93 mm | 4.93 mm | 4.93 mm |
Cash burn (monthly) | 1.32 mm | 593.58 k | 1.12 mm | 1.62 mm | 1.28 mm | 1.53 mm |
Cash used (since last report) | 8.83 mm | 3.96 mm | 7.50 mm | 10.80 mm | 8.51 mm | 10.19 mm |
Cash remaining | -3.90 mm | 966.07 k | -2.57 mm | -5.87 mm | -3.58 mm | -5.26 mm |
Runway (months of cash) | -2.9 | 1.6 | -2.3 | -3.6 | -2.8 | -3.4 |
Institutional ownership, Q2 2023
3.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 104.20 mm |
Total shares | 254.70 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bigger Capital Fund L P | 161.55 k | $184.00 k |
Lind Global Fund II | 54.48 k | $0.00 |
Vanguard | 24.10 k | $64.82 mm |
Susquehanna International | 10.40 k | $27.99 mm |
Tower Research Capital | 3.16 k | $8.50 mm |
UBS UBS Group AG - Registered Shares | 948.00 | $2.55 mm |
JPM JPMorgan Chase & Co. | 58.00 | $156.00 k |
FMR | 2.00 | $5.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Archelle Georgiou Feldshon | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 11,365 | 7.84 k | 11,365 |
2 Jan 24 | David McDonald | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 11,365 | 7.84 k | 11,365 |
2 Jan 24 | Michael Kendrick McCormick | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 20,836 | 14.38 k | 20,836 |
News
Nuwellis Filed U.S. Patent Application #20240108533: VENOUS BLOOD FLOW STIMULATOR FOR EXTRACORPOREAL THERAPY
4 Apr 24
Nuwellis Announced Results From Two New Clinical Data Analyses From The AVOID-HF Trial Demonstrating Benefits Of Aquadex System For Heart Failure
7 Mar 24
Nuwellis Q4 2023 GAAP EPS $(2.240) Misses $(1.390) Estimate, Sales $2.600M Beat $2.551M Estimate
5 Mar 24
Earnings Scheduled For March 5, 2024
5 Mar 24
Earnings Preview For Nuwellis
4 Mar 24
Press releases
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
7 Mar 24
Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
22 Feb 24
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Feb 24